Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2023 | 1 |
2024 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
Br J Dermatol. 2023 Jul 7;189(1):42-52. doi: 10.1093/bjd/ljad115.
Br J Dermatol. 2023.
PMID: 37022762
Clinical Trial.
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ, Ogdie A, Tesser J, Shiff NJ, Zhao RS, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF.
Mease PJ, et al.
ACR Open Rheumatol. 2024 May;6(5):304-311. doi: 10.1002/acr2.11657. Epub 2024 Feb 28.
ACR Open Rheumatol. 2024.
PMID: 38417434
Free PMC article.
OBJECTIVE: Evaluate patient-reported outcomes after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry. METHODS: This analysis includes registry participant …
OBJECTIVE: Evaluate patient-reported outcomes after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active pso …
Item in Clipboard
Cite
Cite